Savara Inc.

NasdaqGS SVRA

Savara Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Savara Inc. Gross Profit Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Savara Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -23,915.70%, a -31,931.73% change year over year.
Savara Inc. Gross Profit Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was 75.13%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NasdaqGS: SVRA

Savara Inc.

CEO	Mr. Matthew Pauls J.D., M.B.A.
IPO Date	April 28, 2017
Location	United States
Headquarters	Building III
Employees	37
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Key trends

Past 5 years